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Abstract 
Parkinson’s Disease (PD) is a debilitating disease which affects 1% of the population worldwide and 
is characterised by stiffness, tremor and bradykinesia. PD is a complex disease with many suspected 
genetic and environmental causes, and it is critical to understand all the pathways involved in 
disease progression to develop effective therapies for PD, which currently has no cure. A kinase-
coding gene, LRRK2 has emerged as a focal point for much PD research, particularly PD-associated 
SNP LRRK2-G2019S, which leads to LRRK2 overactivity. Rab proteins, a series of small GTPases, have 
been identified among the proteins phosphorylated by LRRK2. These interactions may be modelled 
in the fruit fly Drosophila melanogaster. 
Using optogenetics in the fly, this project investigates the relationship between the LRRK2-G2019S 
and Rab10 interaction, and the speed and degree of tremor of Proboscis Extension Response (PER) 
by triggering a PER in fly lines of different genotypes. Significant bradykinesia in Rab10 null flies 
which was not recreated in flies with dopaminergic neuron Rab10RNAi suggests that the bradykinesia 
PER phenotype is caused by off-target effect of Rab10-KO in another tissue of the fly than the 
dopaminergic neurons. Over-expression of Rab10 in dopaminergic neurons of flies also expressing 
LRRK2-G2019S produced resting tremor and inability to fully extend the proboscis. 
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Introduction 
1.1 Parkinson’s Disease 
1.1.1 Phenotype of Parkinson’s Disease 
Parkinson’s Disease is a neurodegenerative disorder found in approximately 1% of the population 
worldwide (de Lau and Breteler, 2006). It is diagnosed by the presence of two out of three of key 
symptoms: bradykinesia, tremor in hands and arms which later spreads to legs and feet, and muscle 
rigidity. However, the defining characteristic of Parkinson’s by which it is differentiated from other 
similar neurodegenerative disorders is the progressive loss of dopamine-containing neurons, and 
responsiveness of the condition to L-Dopa. Conclusive diagnosis may be challenging due to the 
neuron loss being identifiable only post-mortem (Jankovic, 2008). Other symptoms may include loss 
of balance, and various non-motor symptoms, such as worsening eyesight (Armstrong, 2008) and 
depression (Marsh, 2013).  
Beyond discernible physical symptoms, the principle manifestation of PD at the cellular level is the 
presence of Lewy bodies, toxic aggregates composed principally of alpha-synuclein (Spillantini et al., 
1997). Other proteins which may appear in Lewy bodies include ubiquitin and tau proteins, and as 
with tauopathies the Lewy bodies may be associated with neurofibrillary tangles (Zhang et al., 2018). 
Alpha-synuclein is an intrinsically disordered protein which is soluble in the cytosol as a monomer. 
However, exposure to hydrophobic molecules or environment can cause the centre of the protein to 
fold into beta sheets, which may dimerise or form aggregates. One misfolded alpha-synuclein 
protein may influence other alpha-synuclein proteins to fold the same way in order to interact with 
them and create a global free energy minimum (Ulmer et al., 2005). Lewy bodies are extremely 
detrimental to the cell architecture and trafficking, disrupting organelles and contributing to 
degradation of mitochondria and the cell nucleus. Cell death releases Lewy bodies into the brain 
tissue, where they may be taken up by other cells. The prion-like effect of the misfolded alpha-
11 
 
synuclein can therefore be spread through the substantia nigra, the area of the brain where Lewy 
bodies are commonly found in PD (Power et al., 2017). Nine clusters of dopaminergic neurons are 
found in the mammalian brain. 95% of these dopaminergic neurons are represented in the 
substantia nigra region of the brain, where they comprise 3-5% of the cells. They are responsible for 
control of voluntary movement, and dopaminergic neurons found elsewhere are also involved in 
regulating a number of disparate behaviours including motivation and reward (Chinta and Andersen, 
2005), achieved by projecting into other regions of the brain. Several features distinguish 
dopaminergic neurons from other types of neuron, notably the presence of the enzyme tyrosine 
hydroxylase, responsible for conversion of tyrosine into L-Dopa, a precursor molecule for dopamine. 
L-Dopa is decarboxylated to complete dopamine production. Tyrosine hydroxylase is coded for by 
gene TH, which is highly conserved between species; the homologue in Drosophila melanogaster is 
Pale, with a central coding domain containing 80.5% sequence identity. Deleterious mutations in TH 
cause Segawa syndrome, which manifests Parkinsonian features and responds to L-Dopa (Goswami 
et al., 2017). 
1.1.2 Genetics of Parkinson’s Disease  
PD is a complex disorder with variability regarding type and severity of phenotype, age of onset, and 
genetic aetiology. Several mutations in candidate genes have been discovered in families causing 
versions of Parkinson’s with an earlier age of onset than average, and may also cause faster 
neurodegeneration (Houlden and Singleton, 2012). Principally this has revolved around alpha-
synuclein (Singleton et al., 2003, Polymeropoulos et al., 1997). Mutations or CNVs in the region of 
SNCA, the gene coding for alpha-synuclein, have been found to increase incidence of alpha-synuclein 
aggregation. The rarity of SNCA mutations, with only three deleterious mutations reported in 
families (Kruger et al., 1998, Zarranz et al., 2004) and lack of these mutations in the general 
population, is evidence for the scale of damage to the cells which may be caused by any alteration in 
the structure and concentration of alpha-synuclein. Other candidate genes for PD often code for 
proteins involved in intracellular membrane trafficking, such as LRRK2 (leucine rich repeat kinase 2), 
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MAPT, GBA, and VPS35 (Reed et al., 2018). Mutations in MAPT (microtubule-associated protein tau) 
causing Parkinsonism is not thought to be associated with development of Lewy bodies or alpha-
synuclein abnormalities, but further suggests a critical role for the cytoskeleton and transport within 
the cell in the search for genetic causes and therapies for PD (Wray and Lewis, 2010). Meanwhile, 
genome-wide association studies (GWAS) have indicated multiple small effect alleles that may 
increase susceptibility to environmental factors in the general population, or interact with each 
other to produce a larger effect size. Indeed, GWAS indicates that LRRK2 is a risk factor for PD. 
However, no high-risk common alleles for PD have been discovered (Fung et al., 2006, Maraganore 
et al., 2006). Much of ongoing PD research has focused on identifying interaction maps for the 
protein products of genes with known PD association. Overall, mutations in/near LRRK2 are the most 
common genetic cause of PD. These include the amino acid substitutions G2019S and I2020T. 
In order to understand more about the link between LRRK2 mutation and neurodegeneration, a 
number of labs have created transgenic rodent models using LRRK2 manipulations. These have been 
inconsistent, and do not reliably recapitulate the PD phenotypes (Beal, 2010). This may be because 
they do not make the neuromelanin which gives the substantia nigra its dark colour (Barden and 
Levine, 1983, Marsden, 1961), or due to differences in dopamine metabolism between humans and 
rodents (Burbulla et al., 2017). However, fly models of PD have been successfully exploited as a 
model of PD (Whitworth, 2011). 
1.2 Drosophila as a model organism 
1.2.1 Analysis of Drosophila as a model organism for PD 
Drosophila melanogaster has emerged as a standout model organism in which to model PD and 
other neurodegenerative diseases due to several unique aspects. It has a genome which has been 
highly characterized over decades of study, and which contains homologs of 75% of human disease 
loci (Reiter et al., 2001). The wide scale of effect size seen in humans may be easily mimicked in 
Drosophila. Drosophila also has a short generation span permitting faster crosses than mammalian 
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models, and several powerful genetic tools are available in Drosophila making complex research 
possible.  
They are easy to store and maintain, and allow for large scale, high-throughput projects which would 
not be possible with a larger and more complex organism, such as mice. An additional advantage 
when studying neurodegenerative disease is the shorter time until onset of symptoms due to the 
shorter lifespan of Drosophila. Modelled in rodents, it is possible that two years could be necessary 
to see the same PD symptoms which are present in Drosophila after 28 days (Cording et al., 2017, 
Dawson et al., 2010). Yeast has often been used to observe the biochemistry of protein aggregates 
commonly found in neurodegenerative disease, however when considering the effects on an entire 
complex system, Drosophila is an ideal model organism to use for Parkinson’s Disease due to the 
segmented brain and high visual capacity (Cauchi and van den Heuvel, 2006). The simplicity of the fly 
brain makes it easier to work with, although it may also prevent the fly from being a good model for 
a human brain when more complex functions are involved in a disease. 
Drosophila brains consist of 135,000 neurons, surrounded by glial cells. The brain is divided into two 
mushroom body structures projecting out from a central complex. Mushroom bodies, common in 
insects and arthropods, are packed cell somata which form three distinct lobes. 15 dopaminergic 
neuron clusters have been identified in flies, increasing from 9 in humans. These clusters project into 
multiple different regions of the fly brain, which is consistent with the wide-ranging activities which 
dopaminergic neurons are responsible for (Hartenstein et al., 2017). Many aspects of the fly brain 
morphology are extremely different from the human brain. However, processes in and between 
dopaminergic neurons are well-conserved between humans and flies at a molecular level, and share 
many of the same functions. The earlier described process of dopamine synthesis involving TH is 
conserved between humans and Drosophila, and Drosophila dopaminergic neurons are responsible 
for control of voluntary movement and reward behaviours as in humans, allowing the use of 
Drosophila as a model for human diseases of dopaminergic neurons.  
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Many of the most detrimental problems seen in Parkinson’s disease are also seen in fly models: 
bradykinesia (slowed movement), akinesia (difficulty initiating movement), tremor, and loss of 
dopaminergic neurons (Whitworth, 2011, Cording et al., 2017). 
When using Drosophila as a model organism, it must also be noted that the model has several 
disadvantages. Lack of a blood-brain barrier prevents precise modelling of drug delivery; therefore 
validation of any pharmaceutical trials must be validated in organisms which have a similar delivery 
system to humans. 
1.2.2 The genetics of Drosophila 
Drosophila melanogaster have four pairs of chromosomes. Chr4 is extremely small and the majority 
of work in Drosophila genetics is therefore performed using only the first three. These chromosomes 
have the advantage of well-established balancer chromosomes, which are used when deleterious 
mutations, or disadvantageous transgenic fly lines need to be maintained. These prevent the desired 
mutation from being lost from the population, and also to prevent alleles of interest on the same 
chromosome being separated by recombination. Balancer chromosome homozygosity is lethal, but 
flies which carry a heterozygous mutation and balancer chromosome can be identified by the 
dominant marker or markers found on the balancer chromosome. Balancer chromosomes are 
available for each chromosome: FM7 causes a bar eye phenotype and is a balancer chromosome for 
chromosome 1, CyO causes curly wings and is a balancer chromosome for chromosome 2, and TM6B 
causes extra bristles on the thorax and is a balancer chromosome for chromosome 3.  
1.2.3 Gal4-UAS system 
The UAS-Gal4 system is part of the Drosophila genetic toolkit (Brand and Perrimon, 1993). It is a 
binary expression system, using genes originally discovered in yeast, but not present in the fly 
(Figure 1A). A transgene is created by inserting the transcriptional activator Gal4 along with a 
characterised driver or promotor gene into the fly genome. The promotor then determines which 
cells will express Gal4. Where the driver is transcribed, Gal4 will also be expressed, while in all other 
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cells where the driver is silenced, the Gal4 protein will not exist as Gal4 is not normally present in 
the Drosophila genome. The expression of Gal4 has no effect on normal Drosophila cells, but when 
the upstream activating sequence (UAS) is also present in the genome, Gal4 will bind and activate 
transcription of the gene immediately downstream of the UAS. Thus to complete the system, a 
second transgene can be created of the UAS sequence, and a target or reporter gene immediately 
following it. A normal technique to generate a fly line containing both transgenes is to cross a fly 
with promotor-Gal4, where the promotor is expressed in the specific cells of interest e.g. neurons, 
with a fly with UAS-target, resulting in offspring with both genes. Thousands of fly lines have been 
created using Gal4 or UAS transgenes, which can be crossed to create desirable combinations of 
gene to be expressed, and the location it is to be expressed in.  
Here we deployed the GAL4-UAS system to express the Parkinson’s disease related gene, LRRK2, in 
the dopaminergic neurons. This leads to a number of phenotypes, both motor (Cording et al., 2017), 
and non-motor (Hindle et al., 2013), so replicating the human disease. Notably, dopaminergic 
expression of the G2019S and I2020T  forms of  LRRK2 results in a slower proboscis extension 
response (Cording et al., 2017), due to the action of the mutant protein in a single dopaminergic 
neuron, the TH-VUM (Marella et al., 2012).  
One of the problems noted with sucrose stimulation of the Proboscis Extension Response was 
variability in the operator’s application of the sucrose droplet to the legs. The experimental 
approach could be much improved by a more defined and precise stimulus, here an optogenetic 
activation of the sucrose-sensing neurons. Although the collection of available UAS lines contains a 
number of possible light-activated ion channels (channelrhodopsins), these would not permit 
independent expression of LRRK2 and the channelrhodopsin (ChR). To circumvent this we turned to 
a second binary expression system, LexA-LexAop. 
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1.2.4 LexA-LexAop system 
The LexA-LexAop system is based on the same idea as the GAL4-UAS, a two component expression 
system. LexA is a bacterial transcription factor which, when it has been fused with a C-terminal 
activation domain from GAL4 or VP16 (Sadowski et al., 1988), drives transcription of any reporter 
gene with a LexAop sequence present in its promoter region for LexA to bind to (Figure 1B). Since 
the LexA-LexAop system uses a bacterial rather than a yeast transcription factor, it is completely 
separate to the UAS-Gal4 system, allowing them to be used as complementary systems to control 
targeted expression of different proteins in different cell types. Examples of applications of the two 
systems in duality include mosaic tissue analysis (Lai and Lee, 2006). The LexA-LexAop system has 
Figure 1. Two binary expression systems used in Drosophila. A. Gal4-UAS (Lynd and 
Lycett, 2011) B. LexA-LexAop. The two systems do not interfere with each other and 
can be used simultaneously.  
 
 
Figure 1. Two binary expression systems used in Drosophila  
A 
B 
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been used to provoke desired behavioural responses in flies by driving ChRs to be expressed in 
neurons responsible for activating various behaviours (Inagaki et al., 2014). 
Gr5a is the gene coding for Gustatory receptor 5a, found in sugar-activated chemosensory neurons 
on the fly’s front legs (Dahanukar et al., 2007, Cording et al., 2017). Activation of the sugar neurons 
usually occurs when the fly has encountered food, and through a cascade of activations in the 
interneuronal pathway, contracts the M3 muscle and causes it to reach out its proboscis as a reflex 
(Cording et al., 2017). The entire signal from stimulus to beginning the proboscis extension is 
transmitted in a few milliseconds. Gr5a can be attached to LexA in the LexA-LexAop system, and thus 
when Gr5a is activated, Gr5aLexA will also drive transcription of the LexAop transgene, so that 
translation of the protein coded for by the gene recombined with LexAop will also be expressed in 
Gr5a-neurons. 
ReaChR is a red-shifted variant of channel rhodopsin, a family of light-gated channels which 
selectively depolarise cells in which they are expressed when activated by the wavelength of light to 
which they are sensitive. Most ChRs are activated by light with wavelength of 450-545nm, 
wavelengths which may not penetrate deep into the brain due to being absorbed by common 
proteins. ReaChR is instead activated optimally by 627 nm (red), although 470-655 nm wavelengths 
have been employed with success. ReaChR is fully described by Lin et al, 2013. In LexAop-ReaChR 
flies, where the transgene LexAopReaChR is under the control of LexAop, ReaChR protein will only be 
expressed in the neurons with LexA. Crossing Gr5a-LexA and LexAop-ReaChR lines produces flies 
which express ReaChR channels in the membranes of sugar-activated chemosensory cells. Thus, 
activation of ReaChR channels by light will produce the same response as if the fly had encountered 
sugar, but the proboscis extension reflex will be immediately triggered in a temporally and spatially 
defined manner. 
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1.3 LRRK2 
LRRK2 is an autosomal dominant gene encoding a large protein of 286kDa (Cook et al., 2017). 
Genome-wide linkage first identified the gene in a Japanese family with Parkinsonian symptoms 
(Funayama et al., 2002), and since then mutations occurring in LRRK2 have been identified as 
contributing to 1-2% of PD cases and between 3% and 41% of familial Parkinson’s occurrences 
(Kachergus et al., 2005, Lesage et al., 2005, Mata et al., 2005, Nichols et al., 2005). The protein 
LRRK2 contains several domains which perform different functions (Figure 2), notably including a 
serine-threonine kinase. The large number of domains capable of different protein interactions 
allows LRRK2 to interact with many different proteins, and thus it is capable of involvement in 
multiple distinct signalling pathways and activities within the cell.  
 
 
 
 
 
LRRK2 can contain several different pathogenic SNPs which have been associated with late-onset PD, 
such as I2020T and G2019S (Healy et al., 2008b) in the kinase domain and R1441C/G (West et al., 
2005) in the GTPase domain. Meanwhile, alpha-synuclein mutations are more associated with early-
onset PD (Houlden and Singleton, 2012). Many of the PD-associated SNPs have been found to 
increase LRRK2 kinase activity. Differences in alpha-synuclein pathology between autopsied PD 
patients with known LRRK2 mutations suggests that mechanisms of LRRK2 pathology are conducted 
at least partially separately to pathways increasing alpha-synuclein aggregation. G2019S, the most 
common LRRK2 mutation, increases kinase activity at least twofold, and I2020T and other LRRK2 
Figure 2. Map of LRRK2 domains. The positions of PD-associated SNPs R1441C and 
G2019S are also mapped. The ROC and kinase domains, which contain the majority of 
pathogenic SNPs, are the two domains with enzymatic activity. Created using Adobe 
Illustrator 
Figure 2. Map of LRRK2 domains 
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mutations in the GTPase domain also increase kinase activity (West et al., 2005). However, 
incomplete penetrance is indicated, as extreme variance is seen in development and progression of 
PD, including whether the affected individual sufferer has Lewy bodies (Marti-Masso et al., 2009, 
Hasegawa et al., 2009). 
Given the number of different pathways LRRK2 operates in, it is critical but non-trivial to discover all 
the putative mechanisms by which LRRK2 overactivity may contribute to dopaminergic neuron decay 
and development of Parkinsonian symptoms.  
1.3.1 Interactions of LRRK2 
 
LRRK2 has a role in endolysosomal trafficking and autophagy, two highly cooperative intracellular 
processes. Lysozymes have been shown to be missorted to lysosomes in LRRK2-KO mice due to the 
lack of Rab2a recruitment to the vesicles that would exocytose the lysozymes, resulting in 
susceptibility of the mice to listeria infection (Zhang et al., 2015). This may provide a link between 
LRRK2 mutations and the failure of PD dopaminergic neurons to remove Lewy Bodies. After alpha-
synuclein and other proteins were sent to the lysosome for degradation, increased activity of LRRK2 
caused hyper-phosphorylation of Rab proteins, which migrated to the lysosome membrane and 
initiated premature exocytosis of unfolded alpha-synuclein from the lysosome. These aggregates 
may then be engulfed by other cells in the substantia nigra. However, although co-localisation of 
alpha-synuclein and LRRK2 has been found (Guerreiro et al., 2013) and expressing LRRK2-G2019S in 
alpha-synuclein A53T mouse lines exacerbates degeneration of dopaminergic neurons (Lin et al., 
2009, Daher et al., 2012), no direct evidence has been found to conclude whether these processes 
represent protein interactions or separate mechanisms.  
It is suggested that LRRK2 phosphorylates Tau protein, either directly (Kawakami et al., 2012) or by 
mediating Tau phosphorylation by CDK5 (Shanley et al., 2015), causing its dissociation from 
microtubules necessary for dendrite growth and potentially contributing to the 
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hyperphosphorylated Tau aggregates known as neurofibrillary tangles. However, while many PD 
cases may contain both LRRK2 mutations, and Tau aggregates in some form (Ujiie et al., 2012), there 
are many further potential mechanisms yet to be examined. 
The same LRRK2 mutation may produce drastically different phenotypes, even within the same 
family. This reduced penetrance suggests that the mutated variants of this protein increase 
susceptibility to environmental or other genetic factors rather than directly impact disease 
progression. It has been established that the rate of LRRK2-G2019S-influenced neurodegeneration is 
increased by greater energy demands placed on neurons (Hindle et al., 2013).  
 
Continued prevalence of deleterious SNPs in LRRK2 within the population may be due to 
antagonistic pleiotropy. As PD onset typically occurs considerably later than reproductive years, 
advantageous effects being conveyed in early life, such as faster cognition and better eyesight 
(Himmelberg et al., 2018), would be experienced long before the debilitation of PD. In other 
instances, deleterious SNP-prevalence could be due to founder effect in particular populations such 
as the Berbers of North Africa (Lesage et al., 2005). 
 
Due in part to the contribution of LRRK2 to both familial and non-familial PD, LRRK2 inhibitors are 
being investigated for therapeutics (Chan and Tan, 2017, Galatsis, 2017). With LRRK2 being 
considered as a target for treatment, it is even more crucial to discover the full pathway by which it 
is involved in development of PD. LRRK2 highly expressed in the brain, but is also found in high 
concentrations in the lungs and kidneys (Giasson et al., 2006). Concerns have been raised that lung 
and kidney toxicity may arise when LRRK2 inhibitors are used as PD treatment, as well as the 
potential for infections if the immune system role of LRRK2 is compromised (Baptista et al., 2013, 
Fuji et al., 2015). However, inhibiting a target protein downstream of LRRK2 in the same pathway 
could potentially avoid some or all of these issues. 
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Using a combination of data mining and protein microarray screening (embryonic kidney-based cell 
line), Tomkins et al., (2018) have developed a list of putative interaction partners of LRRK2. 
Experimentally, in the microarray screening, 78 proteins were found to interact with LRRK2, and 
though these have not all been verified in vivo, the implication is that LRRK2 is a non-specific kinase, 
capable of interacting with many proteins given co-localisation and the correct conditions. 
 
Using mouse models with overactive LRRK2 protein, or a LRRK2 protein with normal activity but 
impervious to inhibition, Steger et al., (2016) were able to identify phosphopeptides which had been 
phosphorylated in vivo by LRRK2 and were therefore up- or down-regulated in the respective 
screens. The proteins were then determined by liquid chromatography-mass spectrometry, the 
techniques used together to give more robust results than previous studies where a single technique 
was employed. 14 Rab GTPases including Rab8A, Rab10, and Rab12, were found to be 
phosphorylated by LRRK2 on a conserved Thr residue in the Switch 2 domain. This experiment was 
the first to accurately determine only those kinase interactions which could occur in vivo, although it 
had the limitation that only proteins which LRRK2 phosphorylated would be identified, when LRRK2 
is capable of interacting with other proteins in a myriad of other ways due to the multiple functional 
domains it possesses. However, it was noted that pathogenic LRRK2 mutations in the GTPase or WD-
40 domains also increased the concentration of phosphorylated Rab8a and Rab10 in vitro.  
1.3.2 Rab GTPases 
Rab GTPases are small GTPases which regulate intracellular trafficking via the recruitment of effector 
proteins to aid vesicle creation, function, movement, and fusion (Eguchi et al., 2018, Pylypenko et al., 
2018). There are 33 distinct Rab proteins in flies, and an estimated 70+ in humans, of which 23 fly 
proteins are direct homologues of human proteins. The basic structure of Rabs, which comparative 
to LRRK2 are small proteins of around 20-30 kDa (Pereira-Leal and Seabra, 2000), have a GTPase 
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domain of α-helices and β-sheets linked to an intrinsically disordered C-terminal sequence which is 
prenylated immediately after translation to allow membrane-embedding (Kiral et al., 2018). This 
disordered sequence likely determines which membrane the Rab is transported to after translation, 
and unlike the GTPase domain, it is not conserved between Rabs, or between species. The GTPase 
domain contains a nucleotide-binding P-loop, Switch 1, and Switch 2 (Figure 3).  
 
Figure 3. 3D structure of Rab3A (Pylypenko et al., 2017). 
 
 
After a Rab has been inserted into the membrane of an organelle, vesicle, or cell, anchored by its 
geranylgeranyl lipid modification, it is active and able to recruit effector proteins when it is bound to 
GTP, and inactive when it is GDP-bound, thus functioning as a molecular switch (Zhen and Stenmark, 
2015). Activation occurs when GDP is released and replaced with GTP, a slow process which must be 
catalysed by a Guanine nucleotide exchange factor (GEF). The GEF induces conformational change to 
the P-loop, Switch 1, and Switch 2 domains of the Rab protein with which it interacts, allowing the 
release of GDP. As with release of the GDP, GTP hydrolysis is a slow reaction requiring a catalyst. An 
arginine or glutamine residue present in (GAPs) interacts with the GTP-bound Rab, allowing it to 
maintain stability whilst releasing a phosphate group from GTP, hydrolysing to GDP (Vetter and 
Wittinghofer, 2001, Figure 4). 
Figure 3. 3D structure of Rab3A (Pylypenko et al., 2017). Switch 1 (red) and Switch 
2 (blue) are labelled. The phosphate group on Switch 2 interacts with the GTP third 
phosphate group. Complementarity determining regions (CDRs) are also labelled.  
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When a Rab protein is being recycled from an acceptor membrane to a donor membrane, it is 
inactive in the cytosol, tightly bound to a guanosine nucleotide dissociation inhibitor (GDI). Although 
the full and precise mechanism by which a Rab protein may be extracted from the GDI which it is 
bound to in the cytosol is unknown, it is likely that phosphorylation by LRRK2 of the conserved 
residue in the Switch 2 region helps to facilitate this, as the GDI would be positioned closely to the 
Switch 2 region in the GDI-Rab complex, but cannot achieve this conformation after phosphorylation. 
Once the Rab protein has been extracted from this complex, possibly with the aid of a GDI-
displacement factor (GDF) (Dirac-Svejstrup et al., 1997), it can be inserted into a donor membrane 
Figure 4. The life-cycle in the cell of a small GTPase protein, such as a Rab protein. (Bento et 
al., 2013) 
Figure 4. The life-cycle in the cell of a small GTPase protein, such as a Rab protein 
24 
 
and activated. However, Purlyte et al., (2018), suggest that GDIs are also necessary for delivery of 
Rab proteins to membranes. 
Many proteins bind to non-phosphorylated Rabs preferentially other than GDIs. Rab 
geranyltransferase complex members (CHM, CHML, and RabGGTA/RabGGTB) are responsible for the 
prenylation of Rabs prior to their embedding in the target membrane. The Rab8a guanine nucleotide 
exchange factor Rabin8, which has been found to activate both Rab8a and Rab10 to promote neurite 
outgrowth (Homma and Fukuda, 2016), also has less activity interacting with Rabs when they have 
been phosphorylated (Steger et al, 2016), implying that GEFs generally may have less interaction 
with phosphorylated Rabs than non-phosphorylated Rabs. 
Rabs have also been linked to neurodegeneration independently of LRRK2. Rab11 co-localises with 
alpha-synuclein, and is thought to interact with it (Chutna et al., 2014) and overexpression of Rab11 
was able to partially rescue the effects of alpha-synuclein toxicity (Breda et al., 2015). Rab35 levels 
have been found to be increased in PD patient serum compared to healthy controls and 
neurodegenerative disease controls, and overexpression of Rab35 was found to cause 
neurodegeneration in mouse brains (Jeong et al., 2018). Rab35 is also phosphorylated by LRRK2, and 
Rab35 may positively regulate alpha-synuclein propagation (Bae et al., 2018). Several Rab proteins – 
Rab8A, Rab8B, and Rab13 – are substrates of PINK1, another PD-related protein (Lai et al., 2015). 
1.3.3 LRRK2 interactions with Rab GTPases 
Verification that LRRK2 directly phosphorylates Rab10 was performed has been performed (Steger 
et al., 2016). Rab10 and LRRK2 were incubated in a solution containing [-32P]ATP, before the 
products were separated on SDS-PAGE gels and digested with Trypsin. Identified phosphopeptides 
were analysed by LC-MS and the T73 residue in Rab10 was identified as the phosphorylation site by 
solid-phase Edman degradation. Further validation carried out in G2019S-expressing human 
embryonic kidney cells, where it was found that levels of P-T73-Rab10 decreased when a LRRK2-
inhibitor was introduced. Sequence analysis on the 14 Rabs determined to be phosphorylated by 
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LRRK2 revealed that these are not the selection of Rabs with the highest sequence similarity, but 
rather a selection of different Rabs. It is therefore suggested that these are the Rabs which colocalise 
to the same areas of the cell as LRRK2 (Steger et al., 2017). Subsequent to this work, the Alessi lab 
also trialled use of Phos-tag acrylamide to assess Rab10 phosphorylation in a more high-throughput 
fashion by slowing process of tagged phosphorylated Rab10 through a gel, and reported that Rab10 
phosphorylation was blocked when LRRK2 was knocked down (Ito et al., 2016), before identifying 
antibodies specific to T73-phosphorylated Rab10 (Lis et al., 2018). They suggest that quantification 
of phosphorylated Rab10, possibly in peripheral blood neutrophils, may be a useful tool in 
measuring the efficacy of LRRK2 inhibitors in therapeutics (Fan et al., 2018, Lis et al., 2018). 
 
Due to the relative ease of measuring P-T73-Rab10 with this antibody, and its considered 
importance as a down-stream target of LRRK2, further experiments by the Alessi lab have 
considered the effects of other LRRK2 interactions with further proteins in the same signalling 
pathways, on Rab10. VPS35, a regulator of vesicles in intracellular trafficking (Progida and Bakke, 
2016), and Rab29 are key upstream regulators of LRRK2. Rab29 is one of five genes located at 
genetic locus PARK16, and an interaction between LRRK2 and this locus has been previously linked 
to PD. Meanwhile, overexpression of Rab29 has been found to rescue the shortened neurites 
phenotype found when pathogenic LRRK2 mutations and truncated Rab29 protein were expressed 
together (MacLeod et al., 2013). Rab29 regulates LRRK2 by interacting with its ankyrin domain. 
Subsequently phosphorylation of a key LRRK2 biomarker region between the ankyrin and kinase 
domains occurs, and LRRK2 localises to the Golgi apparatus or lysosome (Purlyte et al., 2018). 
Purlyte et al suggest that this mechanism could be duplicated with other Rabs at other membrane 
locations in order to activate LRRK2 around the cell. Rab29 is certainly not the only activator of 
LRRK2, as LRRK2 phosphorylated Rab10 even in Rab29-KO cells.  
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VPS35, which forms a complex with other proteins capable of activating LRRK2 (Figure 5), was first 
identified in several affected families (Vilarino-Guell et al., 2011). VPS35-D620N, a gain-of-function 
mutation, has been shown to up-regulate LRRK2-mediated phosphorylation of Rab10 in mouse lung, 
kidney, brain and spleen 6-fold, more than any known mutations in LRRK2 itself. PD patients with 
this SNP suffered corresponding phenotypes, with lower average age of onset (Mir et al., 2018). 
VPS35 is also located at the Golgi apparatus, and it is interesting that recruitment of LRRK2 to the 
Golgi results in loss of Golgi integrity, which could also be related to PD, although the mechanism by 
which this takes place is unknown (Purlyte et al., 2018). 
 
 
 
 
 
 
 
 
 
 
Figure 5. A putative pathway for LRRK2 
Figure 5. A putative pathway for LRRK2 (Mir et al., 2018). Up-regulation or overexpression of any 
protein component of this pathway may lead to Parkinson’s disease, and all may be therapeutic 
targets. 
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1.3.4 Rab10 as a possible mechanism for LRRK2 pathology 
Of the cohort of Rabs identified as LRRK2 substrates, Rab10 appears to have a much larger range of 
cell localisations and functions than most other Rab proteins, and thus over-phosphorylation of 
Rab10 is thought one of the most likely pathways to be a contributing factor to the development of 
PD. Increased expression of phosphorylated Rab10 has also been found in dopaminergic neurons of 
PD patients (Di Maio et al., 2018). Furthermore, roles for Rab10 have been identified in several 
processes which may influence the degeneration of dopaminergic neurons. 
 
One of the most characterized roles of Rab10 is in mediating translocation of GLUT4 vesicles to the 
cell membrane, particularly in adipocytes. GLUT4 storage vesicles (GSVs) respond to insulin signalling 
by moving to and fusing with the plasma membrane, enabling expression of the GLUT4 glucose 
transporters on the cell surface for uptake of glucose to the muscles and adipose cells (Jaldin-Fincati 
et al., 2017). Rab10 is present in the membranes of GSVs in adipocytes (Larance et al., 2005). Insulin 
binding to the insulin receptor activates the PI3K pathway, resulting in the activation of Atk, which in 
turn phosphorylates AS160, a Rab-GTPase activating protein. AS160 switches on Rab10 by catalysing 
GDP-GTP exchange, and active Rab10 enables GSV translocation and docking. The mechanism for 
this is partially unknown, but it is likely that Rab10 recruits Myosin-Va, a molecular motor (Yoshizaki 
et al., 2007, Chen et al., 2012). With hyperactive LRRK2 causing the breakdown of the Rab10 cytosol-
membrane recycling equilibrium, one effect would be to inhibit movement and fusion of GSVs, and 
limit the expression of GLUT4 transporters on the cell surface. 
 
Phosphorylation of Rab10 by LRRK2 occurs as a response to lysosomal stress. Rab29 recruits LRRK2 
to the overly full lysosomes, and LRRK2 is activated by the phosphorylation of the region between its 
kinase and ankyrin domains. LRRK2 is then able to phosphorylate Rab10 and Rab8, maintaining them 
on the lysosomal membrane and preventing their recycling. The Rab proteins then recruit effector 
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proteins EHBP1 and EHBP1L1, which increase protein secretion out of the lysosomes, possibly by 
means of vesicle formation to transport some of the lysosomal contents away (Eguchi et al., 2018). 
EHBP1 may also be recruited by Rab10 to aid lipid droplet engulfment by the autophagic membrane; 
in this instance EHD2 is also recruited, and the three form a complex between the autophagosome 
and lipid droplet (Li et al., 2016). 
 
Rab10 has also been shown to have a role in mitophagy, adversely affected by over-phosphorylation 
by LRRK2. Mitophagy is of critical importance to the health of the cell, as defective mitochondria 
may produce excess reactive oxygen species (ROS) and release proapoptotic factors. Mitochondrial 
membrane potential is a key indicator of healthy mitochondrial function, as the membrane potential 
cannot be used to drive ATP production once it has dropped below a certain threshold; therefore, 
mitochondria depolarised below this threshold are tagged for destruction by mitophagy (Twig and 
Shirihai, 2011). Rab10 is recruited to depolarised and ubiquitin-labelled mitochondria, where it 
inserts into the membrane using its post-translational prenylation modification. Subsequently Rab10 
binds OPTN, one of five primary autophagy receptors which are recruited to the mitochondria 
membrane. This is one of several mechanisms by which OPTN accumulates on the surface of the 
mitochondria, in accordance with the high volume of OPTN which is necessary for mitophagy to take 
place (Weil et al., 2018). However, the significant increase of T73-Rab10 phosphorylation caused by 
gain-of-function LRRK2 mutants impairs Rab10-OPTN binding, and mitophagy is disrupted (Wauters 
et al., 2019). Thus, defective mitochondria are not undergoing mitophagy at a normal rate, if at all, 
and the cells are at higher risk of damage from ROS and of undergoing apoptosis due to the release 
of proapoptotic factors. Oxidative stress, of which ROS are a principle cause, may also disrupt the 
binding of LRRK2 to activity-limiting 14-3-3 proteins and increase LRRK2 kinase activity even further 
(Lavalley et al., 2016, Di Maio et al., 2018). Mitochondria dysfunction has been reported in LRRK2 
mutant cells, and was shown to be rescued by overexpression of Rab10, or by LRRK2 inhibition 
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(Wauters et al., 2019). It is notable that ROS-induced increase of LRRK2 kinase function would 
provide a mechanism by which LRRK2 activity may be responsible for aspects of PD development in 
more sufferers than just those with a LRRK2 gain-of-function mutation, giving greater potential 
impact to therapeutics which may be developed with LRRK2 and its substrates as targets. 
 
Rab8A and Rab10 have also been identified as playing an important role in growth and development 
of cell cilia. It has been suggested that the role of Rab10 in ciliogenesis is as a suppressor. While 
Rab8A acts to give guidance for the positioning of apical markers, allowing ciliogenesis to begin (Sato 
et al., 2014), Rab10 co-localises to the base of primary cilia with RILPL1, where they prevent the 
creation of further cilia and the extension of pre-existing cilia. This is likely to occur through the 
characterised RILPL1 function of regulating cilia membrane content, specifically removing signalling 
proteins from the membrane (Schaub and Stearns, 2013). Rab10 is also able to initiate this process 
without RILPL1, but the opposite is not true (Dhekne et al., 2018).  
 
Dhekne et al (2018) hypothesise that phosphorylation of Rab10 increases its affinity for binding 
RILPL1, and thus when LRRK2 is overactive, more Rab10-RILPL1 complexes are formed and the 
number and growth of cilia are reduced. Overexpression of Rab10 in A549 cells was also shown to 
significantly reduce the number and growth of cilia. Furthermore, when Rab10 or RILPL1 were 
knocked down, no difference in the cilia was observed between cells expressing gain-of-function 
LRRK2 mutations, and those expressing wild-type LRRK2, confirming that the pathway through which 
LRRK2 influences ciliogenesis is Rab10-RILPL1. Neurons and some glial cells are ciliated, and cilia 
have a vital role in the hedgehog (Hh) pathway and other signalling. There may therefore be 
potential for structural or signalling disruption in the brain when cilia protein components of the 
lipid membrane are altered or dismantled. A closer review of Hh signalling particularly reveals that 
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glycoprotein sonic hedgehog (Shh)-expressing dopaminergic neurons have a survival advantage over 
those where this has been ablated, as it provides them with resistance to neurotoxins MPTP and 6-
OHDA. The resistance is generated by cholinergic (ACh) neurons’ response to Shh, as they release 
GDNF, a neurotrophic factor, which is taken back up by the dopaminergic neurons (Gonzalez-Reyes 
et al., 2012). ACh neurons lacking properly functioning cilia are unable to take up Shh, and do not 
secrete GDNF. Interestingly, if this were a contributing mechanism to PD, it would mean that 
hyperactive LRRK2 in the ACh neurons was a cause in dopaminergic neuron death, rather than LRRK2 
activity in the dopaminergic neurons themselves. 
 
1.4 Aims and Objectives 
My project hypothesis is that mechanisms of Rab10, one of the 23 Rabs present in both humans and 
in Drosophila, are affected by the gain-of-function mutations in LRRK2 which contribute to the 
development of PD. Extensive research identifying Rab10 as a substrate of LRRK2 has been 
performed principally in cells. The aim of the project is to investigate this interaction in a model 
organism, to confirm the genuine interaction in vivo. Drosophila melanogaster has been deemed a 
suitable model system in which to carry out this work, as the genome tractability and binary 
expression systems available will allow for the expression of Rab10 and LRRK2 variants to be tightly 
controlled, and because Rab10-KO is embryonic lethal in mice. Experiments will be carried out to 
ascertain whether altering the interactions of LRRK2 and Rab10 can negatively impact the speed and 
degree of tremor with which the fly can extend its proboscis. My objectives are therefore to cross fly 
lines to create Rab10/LRRK2 mutants, combinations and controls, to record the proboscis extension 
responses of these fly lines, and to analyse the footage to identify differences between fly lines in 
speed and tremor. Control lines will contain an optogenetic background controlled by the LexA-
LexAop system, and lines containing additional combinations of Rab10-KO, Rab10 knockdown in 
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dopaminergic neurons, Rab10 overexpression, and LRRK2-G2019S expressed in dopaminergic 
neurons will also be created and analysed. 
Materials and methods 
2.1 Molecular Biology 
2.1.1 Materials 
The TAE buffer required for gel electrophoresis was created from 40mM Tris base, 20mM acetic acid 
and 1mM EDTA. Tris, acetic acid, EDTA and agarose were purchased from Melford. SYBR safe and 
1kb ladder were purchased from Invitrogen. Primers for UAS were a kind gift from Dr Ryan West; all 
others were designed using Primer3 (http://primer3.ut.ee/) and PrimerX 
(http://www.bioinformatics.org/primerx/cgi-bin/DNA_1.cgi) and purchased from Sigma Aldrich.  
 
Table 1. Primers used for genotyping Gr5a and ReaChR 
Table 1. Primers used for genotyping Gr5a and ReaChR  
Gene Primers (5′-3′) PCR product (bp) 
Gr5a FW: TCCTACACGATGGCTCCTTC  REV: GGAGCGATAAAGAGTGCGTG  ~1500 
ReaChR FW: ARGAATTTGATAGCCCGGCG REV: ATCTTCTTCTTCCGCCACCA  ~800 
 
PCRs were performed using Master Mix from Invitrogen and Phusion kits manufactured by 
Finnzymes and Thermo Fisher. ‘Squishing Buffer’ for single fly DNA extraction was made from 10mM 
Tris, 25mM NaCl, and 1mM EDTA with 200ug Proteinase K added fresh to the Squishing Buffer prior 
to DNA extraction.  
Drosophila melanogaster fruit flies were raised on cornmeal-sugar-agar-yeast food as described 
recently (Cording et al., 2017). 
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2.1.2 PCR with Taq  
Primers were designed for genotyping for Gr5aLexA and ReaChR (Table 1). PCR was performed 
according to Invitrogen guidelines, using the cycling conditions in Table 2. 
Table 2. Protocol for PCR using Taq polymerase. 
STEP  TEMP TIME  
Initial Denaturation  95°C  5 minutes 
30 Cycles 
95°C 30 seconds 
53°C 40 seconds 
72°C 1 minute/kb 
Final Extension 72°C 5 minutes 
Hold 4°C   
Table 2. Protocol for PCR using Taq polymerase. 
2.1.3 PCR with Phusion 
PCR was performed according to Thermo Fisher guidelines, using the cycling conditions in Table 3.  
Table 3. Protocol for PCR using Phusion 
STEP  TEMP TIME  
Initial Denaturation  95°C  30 seconds 
30 Cycles 
95°C 10 seconds 
61°C 30 seconds 
72°C 15 seconds/kb 
Final Extension 72°C 5 minutes 
Hold 4°C   
  
Table 3. Protocol for PCR using Phusion 
2.1.4 Gel electrophoresis 
0.7% agarose gels were run at 100V. 
2.1.5 Single fly DNA extraction 
A pipette tip filled with 50ul combined Squishing Buffer and Proteinase K was used to mash a single 
fly in a 2ml tube. The Squishing Buffer was then ejected, and mixed without vortexing. The tube was 
kept at 37°C for 30 minutes, then at 80°C for 2 minutes and subsequently stored frozen until use. 1-
2ul was used for each PCR. 
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2.2 Fly husbandry 
Flies were kept in a warm room of 25°C with 12 hour cycling between light and dark, and fed with a 
solution of 5.5% agar, 22% cornmeal, 20.5% yeast and 52% sucrose. Nipagin was dissolved in ethanol 
and added to the mixture to prevent fungal growth in fly vials.  
2.3 Measuring the Proboscis extension response 
2.3.1 Feeding with retinal 
Male flies were anesthetised and collected the day of hatching and moved into another vial. 24ul of 
retinal in DMSO (40 mM) was diluted in 1 ml 100 mM sucrose giving a 1 mM solution of retinal in 
sucrose. 300ul of this solution was pipetted onto the surface of standard food. The sucrose was used 
to encourage the flies to feed.  
To prevent the flies drowning in the retinal solution, the tube was kept diagonal whilst the flies were 
anesthetised. When the flies were fully recovered, the tube was wrapped in tinfoil and stored for 3 
days in the warm room (25°C). 
2.3.2 Video Measurement of Proboscis Extension Response 
Flies were trapped in pipette tips with the head protruding and secured using nail varnish to 
minimise movement of the head and legs. To ensure the flies would be hungry, and therefore 
responsive to the activation of Gr5a receptors, they were isolated in darkness for 2 to 3 hours.  
The flies were positioned in a rig with a camera recording the fly magnified by a microscope. 470 nm 
wavelength light was flashed at the flies 10 times at regular intervals over 96 ms. The resultant 
proboscis extension responses were recorded in black and white by a Grasshopper 3 (Point Grey) 
camera (Figure 6). The Point Grey ‘Flycapture’ software was used to acquire ~4 seconds of footage at 
258 frames per second, resulting in exactly 1000 frames. The video files were converted to images 
using Fiji (2.0 variant of ImageJ). Two approaches were used to analyse the proboscis extension: one 
to measure the increase in area of the image of the fly as the proboscis was extended, the second to 
measure the distance between the centre of the eye and the tip of the proboscis.  
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Figure 6. Series of frames from a recording of a proboscis extension response 
 
 
 
2.3.3 Measurement of the proboscis extension  
In order to find the movement of the proboscis, code (https://github.com/lcovill/fruit-flies-analysis-
software/blob/master/core.clj) was run on 1000 images captured of each fly categorising each pixel 
as ‘fly’ (white) or ‘background’ (black) according to a darkness threshold which could be altered as 
necessary. The area of the white pixels was calculated for each image (Figure 7). The largest area of  
Figure 6. Series of frames from a recording of a Gr5aLexA::LexAopReaChR control fly proboscis 
extension response 
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Figure 7. Post-analysis visuals of the calculated area of a fly head 
‘fly’ before the area began to decrease again was taken as the end of initial extension, even if the 
area subsequently increased in later images as the fly re-extended its proboscis. The number of 
images from the beginning of the first flash to the initial maximum area was taken to be the duration 
of the initial extension, and the time between these frames in milliseconds was calculated for each 
fly. This approach is robust and straightforward and was used for Figure 11 and subsequently by 
Petridi et al [2019]. However, it did not provide a good estimate of tremor, because the variability in 
the pixel intensity around the edge of the fly head generated excess, false noise in measurement 
between frames. Thus, it was decided to measure tremor using a second approach. 
 
 
 
 
Figure 7. Post-analysis visuals of the calculated area of a fly head (A) An image of the fly 
head prior to light stimulation; (B) the same image after conversion to binary white ‘fly’ and 
black ‘background’; (C) area in red of the extended proboscis. 
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2.3.4 Measurement of tremor in the Proboscis Extension Response  
To calculate the degree of tremor present in the proboscis during the extension, code was written to 
select the lowest white pixel, with the portion of the image taken up by the pipette tip and any 
exposed leg excluded. Thus the lowest edge of the proboscis could be followed, and coordinates 
were generated. The coordinates of the proboscis tip for each fly were deposited into an excel file 
for analysis. Subsequently, coordinates over a threshold of x=400 which were generated when 
flashes occurred were removed.  
 
 
 
 
Figure 8. The Proboscis Extension Response is estimated from the piecewise cubic spline, estimated during each light-off 
period. 
A second, median, filter removed single anomalous outlying coordinates. A problem arose as the 
response usually started before the 10 flashes were complete. In these second and subsequent 
flashes, the whole frame was ‘white’ and the area occupied by the fly was impossible to determine. 
Figure 8. The Proboscis Extension Response is estimated from the piecewise cubic 
spline, estimated during each light-off period.  
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To fill in the position when the flash occurred, a continuous piecewise cubic spline was fitted to the 
data (Figure 8, http://zone.ni.com/reference/en-XX/help/371361P-01/gmath/cubic_spline_fit/). This 
approach was used for the data in Figures 10 and 13. 
2.4 Drosophila melanogaster 
2.4.1 Fly stocks  
Table 4. Fly stocks 
Table 4. Fly stocks; balanced stocks were obtained using routine fly genetics and provided as 
required. Crosses are indicated by / and recombined lines by ::  
Fly stock Abbreviation Source 
Initial stocks 
TH-GAL4 TH Kind gift of Serge Birman 
(Friggi-Grelin et al., 2003) 
w1118 w- Elliott/Sweeney lab stock 
Gr5aLexA Gr5aLexA Kind gift of Kristin Scott 
(Gordon and Scott, 2009) 
w[*]; P{y[+t7.7] 
w[+mC]=lexAop-ReaChR} 
su(Chen et al.)attP5/CyO 
LexAopReachR Bloomington stock 53747 
 
Rab10- Rab10 KO Kind gift of Robin Heisinger 
(unpubl). Deleted region is 
shown in Figure 12. 
y[1] w[*]; P{w[+mC]=UASp-
YFP.Rab10}13 
UAS-Rab10 Bloomington stock 24097 
 
y[1] v[1]; P{y[+t7.7] 
v[+t1.8]=TRiP.JF02058}attP2 
 
Rab10 RNAi Bloomington stock 26289 
(used with UAS-Dicer2, 
Bloomington 24650) 
UAS-G2019S G2019S Kind gift of Wanli Smith (Liu et 
al., 2008) 
Recombined stocks 
TH::G2109S THG2 TH and G2019S on 3rd 
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chromosome 
Gr5aLexA::LexAopReaChR Gr5a::OpR Gr5LexA and LexAopReaChR 
on second chromosome 
 
2.4.2 Fly crosses 
𝐺𝑟5𝑎𝐿𝑒𝑥𝐴
𝐶𝑦𝑂
×
𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅
𝐶𝑦𝑂
 
↓ 
𝐺𝑟5𝑎𝐿𝑒𝑥𝐴
𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅
  (𝐿𝑖𝑛𝑒 1) 
♂ x ♀
𝐺𝑟5𝑎𝐿𝑒𝑥𝐴∷𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅
𝐶𝑦𝑂
  
↓ 
𝐺𝑟5𝑎𝐿𝑒𝑥𝐴 ∷ 𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅  (𝐿𝑖𝑛𝑒 2) 
 
 
𝑤1118  ×
𝐺𝑟5𝑎𝐿𝑒𝑥𝐴 ∷ 𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅
𝐶𝑦𝑂
;
𝑇𝐻 ∷ 𝐺2019𝑆
𝑇𝑀6𝐵
 
↓ 
𝑤1118; 𝐺𝑟5𝑎𝐿𝑒𝑥𝐴 ∷ 𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅; 𝑇𝐻 ∷ 𝐺2019𝑆  (𝐿𝑖𝑛𝑒 3) 
 
 
𝑅𝑎𝑏10𝐾𝑂
𝐹𝑀7
 × 
𝐺𝑟5𝑎𝐿𝑒𝑥𝐴 ∷ 𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅
𝐶𝑦𝑂
;
𝑇𝐻 ∷ 𝐺2019𝑆
𝑇𝑀6𝐵
 
↓ 
𝑅𝑎𝑏10𝐾𝑂; 𝐺𝑟5𝑎𝐿𝑒𝑥𝐴 ∷ 𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅; 𝑇𝐻 ∷ 𝐺2019𝑆  (𝐿𝑖𝑛𝑒 4) 
 
 
𝑈𝐴𝑆𝑅𝑎𝑏10 ×  
𝐺𝑟5𝑎𝐿𝑒𝑥𝐴 ∷ 𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅
𝐶𝑦𝑂
;
𝑇𝐻 ∷ 𝐺2019𝑆
𝑇𝑀6𝐵
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↓ 
𝑈𝐴𝑆𝑅𝑎𝑏10; 𝐺𝑟5𝑎𝐿𝑒𝑥𝐴 ∷ 𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅; 𝑇𝐻 ∷ 𝐺2019𝑆  (𝐿𝑖𝑛𝑒 5) 
 
 
𝑅𝑎𝑏10𝐾𝑂 ×  
𝐺𝑟5𝑎𝐿𝑒𝑥𝐴 ∷ 𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅
𝐶𝑦𝑂
 
↓ 
𝑅𝑎𝑏10𝐾𝑂; 𝐺𝑟5𝑎𝐿𝑒𝑥𝐴 ∷ 𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅  (𝐿𝑖𝑛𝑒 6) 
 
 
𝐷𝑖𝑐𝑒𝑟2
𝐶𝑦𝑂
;
𝑅𝑎𝑏10𝑅𝑁𝐴𝑖
𝑇𝑀6𝐵
 ×  
𝐺𝑟5𝑎𝐿𝑒𝑥𝐴 ∷ 𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅
𝐶𝑦𝑂
;
𝑇𝐻 ∷ 𝐺2019𝑆
𝑇𝑀6𝐵
        
     ↓           
 
𝐺𝑟5𝑎𝐿𝑒𝑥𝐴 ∷ 𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅
𝐷𝑖𝑐𝑒𝑟2
;
𝑅𝑎𝑏10𝑅𝑁𝐴𝑖
𝑇𝐻 ∷ 𝐺2019𝑆
   (𝐿𝑖𝑛𝑒 7) 
 
 
𝐷𝑖𝑐𝑒𝑟2
𝐶𝑦𝑂
;
𝑅𝑎𝑏10𝑅𝑁𝐴𝑖
𝑇𝑀6𝐵
 × 
𝐺𝑟5𝑎𝐿𝑒𝑥𝐴 ∷ 𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅
𝐶𝑦𝑂
 
↓ 
𝐷𝑖𝑐𝑒𝑟2
𝐺𝑟5𝑎𝐿𝑒𝑥𝐴 ∷ 𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅
; 𝑅𝑎𝑏10𝑅𝑁𝐴𝑖   (𝐿𝑖𝑛𝑒 8) 
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Results 
3.1 Reliable optogenetic stimulation of the Proboscis Extension Response  
3.1.1 A Gr5aLexA::LexAopReachR recombination 
Previously flashes of blue light had been used to elicit the Proboscis Extension Response using 
crosses between the driver Gr5aLexA and responder LexAopReaChR. To facilitate further genetic 
manipulations, a potential recombinant stock Gr5aLexA::LexAopReaChR/CyO was provided. DNA 
was extracted from these flies and PCR primers for Gr5aLexA and LexAopReaChR were designed. Gel 
electrophoresis (Figure 9) confirmed that all flies contained both transgenes, while w- controls had 
no bands.   
 
 
 
 
 
 
 
Figure 9. Gel electrophoresis of genotyping for Gr5aLexA and ReaChR. To ensure successful 
recombination of Gr5aLexA and LexAopReaChR had taken place, single fly DNA extraction was 
performed on flies thought to have the genotype Gr5aLexA::LexAopReaChR, and w- control flies. 
Genotyping for ReaChR (600bp) and Gr5aLexA (1500bp) was performed on the extracted DNA using 
Phusion and the primers in Table 1. Lane 1, 1kb ladder. Lanes 2-6, PCR products of 5 
Gr5aLexA::LexAopReaChR line flies genotyped for ReaChR. Lanes 7-10, PCR products of 4 
Gr5aLexA::LexAopReaChR line flies genotyped for Gr5aLexA. Lane 11, PCR products of w- fly 
genotyped for ReaChR. Lane 12, PCR products of w- fly genotyped for Gr5aLexA. Lane 13, 1kb ladder. 
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Figure 9. Electrophoresis gel of genotyping for Gr5aLexA and ReaChR. 
To confirm this biologically, Gr5aLexA::LexAopReaChR  homozygotes were selected and fed retinal 
for 3 days. Their Proboscis Extension Response in response to a flash of blue light was recorded and 
compared with the Gr5aLexA/LexAopReaChR cross. Both lines successfully extended their proboscis, 
demonstrating effective recombination.    
 
3.1.2 Typical proboscis extension response trace 
A typical recording is shown at https://www.youtube.com/watch?v=Zy4qGGrn1ro . In this a series of 
10 flashes is used to stimulate the Gr5aLexA::LexAopReaChR fly, and it extends its proboscis. For 
each dark frame, the area of the fly is measured, and the area increases as the proboscis is extended. 
However, in each flash, the outline of the fly is lost, as during that time the entire frame appears 
white. Distortion may occur due to a pixel elsewhere in the shot being illuminated in a single frame. 
The sample trace shows two examples of this (at ~30 and ~260 frames). Many flies retract the 
proboscis after initial extension (see frames 200-300 of the sample trace) and may or may not re-
extend, while others maintain extension due to subsequent flashes preventing repolarisation of the 
Gr5a neurons.  
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Figure 10. Trace of the tracked proboscis (orange) which is lost during flashes (blue) with fitted continuous piecewise 
cubic spline. 
3.1.3 Analysis of control lines containing Gr5aLexA and LexAopReaChR                                                                                                                             
Two control lines were tested: the Gr5aLexA/LexAopReaChR cross and the Gr5aLexA::LexAopReaChR  
homozygotes. The mean time for the control flies to completely extend the proboscis after the initial 
flash trigger was consistent, with means of the control lines being 393.4  40.3 ms 
Figure 10. Trace of the tracked proboscis (orange) which is lost during flashes (blue) with 
fitted continuous piecewise cubic spline. Proboscis extension occurs after ~60 ms, and is 
complete by 400 ms. Note the two deviant points (black arrows), and the fit between the 
cubic spline and the observed data. After ~1 s, further movements occur. Fly genotype 
Gr5aLexA/LexAopReaChR. 
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(Gr5aLexA/LexAopReaChR) and 412.3  26.0 ms (Gr5aLexA::LexAopReaChR) (Figure 11A). In an 
ANOVA, the post-hoc Dunnett’s T-test showed no significant difference between these lines. 
Although there is a slight difference in latency between these two control genotypes, this is similar 
to the difference in time to fully extend, which was not significant.  
In addition, a third line was used in which two UAS constructs were present, but no GAL4: 
Gr5aLexA::LexAopReaChR/Dicer2; Rab10 RNAi. In this control, the time to peak extension of the 
proboscis was 311  23 ms, not significantly faster than the outcross flies with only 
Gr5aLexA/LexAopReaChR (Figure 11). The latency was 57  24 ms, making the response quite 
variable, and not significantly different from the control outcross. 
 
Figure 11. Flies with both Rab10¯ and TH>G2019S are much slower to extend the proboscis than any other genotype. A. 
Time to reach maximum extension. B. Time to start extending the proboscis 
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Figure 11. Flies with both Rab10¯ and TH>G2019S are much slower to extend the proboscis 
than any other genotype. A. Time to reach maximum extension. B. Time to start extending 
the proboscis. Although there are statistically significant differences in the latency, these are 
small compared with the effect of Rab10¯ and TH>G2019S on the time to fully extend.   
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3.2 Interaction of Rab10 and LRRK2 in vivo 
It was suggested by Steger et al (Steger et al., 2016, Steger et al., 2017) that LRRK2 phosphorylated 
Rab10 and that this was the main action of LRRK2 in vitro. The main purpose of this report is to 
examine this in vivo in the fly model of Proboscis Extension.  
3.2.1 Alignment of human and Drosophila Rab10 
First, a bioinformatics approach was taken to see if it was likely that human LRRK2 might 
phosphorylate fly Rab10. It was necessary to discover whether the sequence of Rab10 conserved, 
particularly at the putative phosphorylation site. 
An alignment was created demonstrating the conservation of Rab10 protein between the human 
and Drosophila systems (Figure 12). The conserved P-loop and Switch 1 and 2 regions were found in 
the amino acid sequences of human and Drosophila Rab10 by using identifiers listed in Coppola et al., 
[2016]. dRab10 and hRab10 are identical in the Switch 2 and P-loop regions, with 1 amino-acid 
difference at the start of Switch 1. However, much of the tail region is not conserved (amino-acids 
170-200) so that the total hRab10 antibody which is targeted at this region is unlikely to recognise 
dRab10. The last four amino-acids – where prenylation occurs – are also identical. Notably, the 
binding site for the phospho-Rab10 antibody (amino-acids 67-80) also has the same sequence. This is 
the site at which LRRK2 will bind and phosphorylate Threonine 73.  All of this suggests that it would 
be feasible for human LRRK2 to phosphorylate dRab10 at an equal rate as it phosphorylates hRab10. 
dRab10 is found in many neurons (Zhang et al., 2007), so that neuronal expression of LRRK2 could 
increase the amount of P-73-Rab10, and this was subsequently demonstrated (Petridi et al, 2019).  
A fly Rab10¯ null was provided, in which the amino acids 21-end were deleted. This deletes the 
entirety of switch 1 and 2, the P-loop, and the tail, so that there is no possibility of LRRK2 interacting 
with any residual protein. No P-73-Rab10 was detected in the Rab10¯ null fly (Petridi et al, 2019).  
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Figure 4. Alignment of human and Drosophila Rab10 protein sequences 
 
3.2.2 Flies with both Rab10¯ and dopaminergic expression of LRRK2-G2019S have a slower 
Proboscis Extension Response.  
                                                                                                                                                                                 
For comparison with the sucrose response of flies expressing LRRK2 transgenes in their 
dopaminergic neurons, the TH::G2019S recombinant was introduced into the optogenetic 
background, Gr5aLexA::LexAopReaChR. When stimulated with blue light, the time to reach the peak 
extension was 381  22 ms (Figure 11), which is not significantly different from the Line 1 control 
Gr5aLexA/LexAopReaChR. Similarly, with Rab10¯ null in the same optogenetic background, the mean 
time to extend the proboscis was 461  31 ms, again not significantly different from the Line 1 
control (Figure 11). 
Figure 12. Alignment of human and Drosophila Rab10 protein sequences. The GTPase 
domain is highlighted in green; the P-loop, Switch 1 and Switch 2 regions in black (Coppola et 
al., 2016); and the deletion in the Rab10 knockout flies in purple. The binding site for the 
Rab10 antibody, the threonine residue which is phosphorylated by LRRK2, and the two 
cysteine residues which are prenylated by Rab geranylgeranyltransferase are also labelled. 
Sequences were procured from UniProt (hRab10 accession no. P61026; dRab10 accession no. 
O15971) and the alignment was created using JalView and edited and labelled in Adobe 
Illustrator. 
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However, when both Rab10¯ and TH::G2019S transgenes were deployed, the Proboscis Extension 
Response took much longer, 579  41 ms, (Dunnett post hoc test, P = 0.0044) (Figure 10). This 
represents a 50% increase in extension time. In this situation Rab10 is eliminated globally, while 
G2019S is expressed in dopaminergic neurons.  
This poses the question of whether it is the Rab10 <--> LRRK2 interaction is dopaminergic neurons 
that is key, or whether LRRK2 has an effect in the dopaminergic neuron, while Rab10 acts in another 
neuron subset or in the muscle. To address this, Rab10 was knocked down using RNAi in the 
dopaminergic neurons. The effectiveness of this RNAi line is shown in western blot for P-T73-Rab10 
(Petridi et al 2019).  
The original cross to generate dopamine specific Rab10 RNAi and G2019S, produced few male 
offspring of the desired genotype Gr5aLexA::LexAopReaChR/Dicer2; Rab10RNAi/TH::G2019S, leading 
to the cross being repeated. The second cross produced more offspring, however all but 2 of these 
died before or during preparation for Proboscis Extension Response, specifically during the 2-3 hour 
incubation whilst trapped in pipette tips. Although proboscis extension responses were achieved 
with these 2 surviving flies, analysis was not performed on the results due to lack of power. The flies 
may not have been able to withstand the 2 hour starvation, due perhaps to too much DMSO (which 
can result in flies eating less), and flies may drown in the solution if they are not completely 
recovered from being anesthetized when the vial is returned to a vertical position. It is noted that 
the dopaminergic expression of Rab10 RNAi and LRRK2-G2019S was subsequently shown to result in 
a slower Proboscis Extension Response (Petridi et al, 2019).   
Finally, the hypothesis that increased dopaminergic Rab10 expression with LRRK2-G2019S might 
generate a phenotype was tested. 
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3.2.3 Effect of increased Rab10 expression 
It was also important to test if additional dopaminergic expression of Rab10, with LRRK2-G2019S, 
affected the flies. UAS-Rab10 and LRRK2-G2019S were both driven by TH-Gal4 in the dopaminergic 
neurons, in the optogenetic background.  In fact, while the mean extension time of 407.75 ± 34 ms 
was not significantly different from the times taken by the control lines, these flies had difficulty fully 
extending their proboscises, with most experiencing a truncated response. This line also experienced 
spontaneous tremor during and after the PER was triggered 
(https://www.youtube.com/watch?v=_0cHnyNpRTg – the tremor and extension can be clearly seen 
at 0.25 speed).  
 
3.2.4 Latency to beginning of the Proboscis Extension Response  
The difference in latency to the start of the PER is statistically significant (F1,6.629 = 6, P < 0.005) 
(Figure 10). However, this difference may be due difficulties in determining the exact start of the 
movement,  as flies of the same line display variation of ~13 ms. Furthermore, the control lines 1 and 
2, which contain no transgenes or mutations, contain the shortest latency (Gr5aLexA/LexAopReaChR, 
mean=59.691.697), and one of the longest latencies (Gr5aLexA::LexAopReaChR, 
mean=73.8284.758). This highlights the difficulty of assessing the start of the PER movement, 
which may be partly obscured by the second light flash. Indeed, in some cases, it is clear that the 
Proboscis Extension Response only began after the second or third flash (Figure 13A).  
3.3 Summary of the effect of LRRK2 and Rab10 variants on the speed of PER 
 
Thus, overall, the data supports the idea that Rab10 and LRRK2 interact in dopaminergic neurons. 
Only the combination of both manipulations in the same neuron was effective in prolonging the 
Proboscis Extension Response.  
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3.4 Tremor of proboscis extension response 
The analysis of the movement of the proboscis allows for the estimation of latency and time to full 
extension. However, in the sucrose stimulated data collected by Cording et al [2017] it was shown 
that the expression of G2019S or I2020T in dopaminergic neurons increased the amount of tremor. 
Tremor was measured as the difference between the actual data and the cubic spline fit (Figure 
13B).  For each trace, the data and cubic spline was calculated, and the absolute value of the 
difference was determined. The median of these absolute differences was calculated for each fly.  
 
 
 
 
 
 
 
 
 
Figure 13. Analysis of the Proboscis Extension Response for tremor. 
Figure 13. Analysis of the Proboscis Extension Response for tremor. Observed data as 
points, fitted cubic spline as red line.  A. Four sample traces. The top and second traces 
(cyan and green) show a short latency response. The third trace (dark blue) shows a much 
longer latency. The lowest trace shows that the analysis fails to measure any extension of 
the proboscis. B. Measurement of the absolute deviation between spline (red line) and 
data, as indicated by the dotted black lines. The data corresponds with the box in A. 
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Figure 14. Dopaminergic expression of LRRK2-G2019S (magenta) increases tremor and this is not blocked by the 
Rab10¯knock-out (yellow). 
Overall, this shows that the tremor is substantially increased when G2019S is expressed in 
dopaminergic neurons. The control flies (Gr5aLexA/LexAopReaChR green bar) have average tremor 
(0.87  0.11) but the dopaminergic G2019S flies have about twice as much (1.78  0.29, magenta). 
This is not affected in the Rab10¯ background (mean 2.05  0.30, yellow bar). As with other fly 
Figure 14. Dopaminergic expression of LRRK2-G2019S (magenta) increases tremor 
and this is not blocked by the Rab10¯knock-out (yellow). Controls are green, Rab10 
overexpression blue, and Rab10 reduction in brown. There is no significant difference 
between the flies expressing LRRK2-G2019S with and without Rab10 
(Gr5aLexA::LexAOpReachR;THG2 against Rab10¯;Gr5aLexA::LexAOpReachR; THG2). 
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phenotypes TH>G2019S flies show a very variable penetrance, with large SE irrespective of the 
presence of Rab10. In the control background, increasing Rab10 (blue) or reducing it (brown) has no 
effect.  
Discussion 
The key results are that the Proboscis Extension Response (PER) can be elicited consistently by 
optogenetic stimulation, that the speed of extension is reduced only in the double transgenic, 
Rab10¯ and TH>G2019S, while just TH>G2019S is enough to induce tremor. The setup also allows us 
to test the accuracy of image digitisation and automated computer analysis of proboscis extension.  
4.1 Differences in the PER of TH > G2019S flies between optogenetic and sucrose 
stimulation  
 
Flies responded reliably to the 10 flashes of blue light, with the PER usually beginning shortly after 
the first flash. In the control lines, almost all the flies responded to the light with a PER, 
demonstrating the efficacy of this method of achieving a PER and reliability of the response once a 
protocol was well-established for these flies. Furthermore, there was no evidence that more 
TH>G2019S flies failed to respond than control flies. This data contrasts with that of Petridi et al 
(2019) where a single flash of light was used as the stimulus. They used the same transgenic 
constructs and apparatus, but found that TH>G2019S flies had a less frequent, slower response – i.e. 
showed both bradykinesia and akinesia. The difference between the data here (where TH>G2019S 
had the same speed of response as controls) and the slower extension described by  Petridi et al 
(2019) may be due to the fact that they kept the flies at 29°C for 7 days to increase expression.   
Equally, it appears that the multiple flashes of light used here generated more action potentials in 
the Gr5a neurons and provided a more reliable stimulus than the single flash of Petridi et al (2019).      
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In the response to sucrose, Cording et al (2017) also found that the TH>G2019S and TH>I2020T lines 
had a slower response than controls, whereas in this project, the mean time to maximum extension 
of the proboscis in TH>G2019S flies was not significantly different to the control flies. Cording et al 
kept flies at 29°C for 3 days after eclosion, increasing the expression of proteins driven by Gal4 as 
stated above. Furthermore, there was an experimental difference in presentation of the stimulus, 
which could lead to a difference in neuronal response. Cording et al (2017) only stimulated the legs 
with sucrose, whereas Gr5a expression occurs in sensory neurons in both proboscis and legs (Chyb 
et al., 2003). The proboscis neurons and leg neurons trigger different responses, with only activation 
of the leg neurons provoking a PER. Proboscis Gr5a-expressing neurons activate taste neurons after 
initial presentation of a food or substance, to signal for further food intake, or rejection. It is possible 
that the proboscis Gr5a and leg Gr5a were stimulated optogenetically, while the sugar solution used 
by Cording et al acted only on the legs; whether or not this is the case, it would occur across all the 
tested lines including controls. 
The standard deviation of proboscis extension speed was high for all the fly lines, but the scatter of 
the data was most for the double transgenic, Rab10¯ and TH>G2019S. Similarly, when the LRRK2-
G2019S allele is expressed in humans, it has extremely variable penetrance (Healy et al., 2008a). This 
indicates that as in humans, LRRK2 and Rab10 do not operate in isolation to cause Parkinsonian 
symptoms in Drosophila, but rather increase susceptibility of the flies to other genetic or 
environmental factors, which combine to cause the slowness and tremor observed in some of the 
flies. 
Both the data presented here and that from Cording et al (2017) indicate that the TH>G2019S flies 
show tremor. In at least some of the flies recorded here, the tremor is seen at rest, with the double 
transgenic (TH>G2019S, UAS-Rab10) showing marked resting tremor. This automated recording of 
tremor, which is not affected by operator variability in sucrose presentation, provides the first 
unbiased measure of the Parkinson’s disease related phenotype in flies. 
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4.2 Analysis of the effect on PER by Rab10 knock-out 
 
The double transgenic Rab10¯ and TH>G2019S, shows a synthetic bradykinesia phenotype, as 
neither the Rab10¯ (Line 6) nor the TH>G2019S (Line 3) lines show this phenotype. The Rab10¯ is a 
global null, and the TH>G2019S is dopaminergic expression.  In extending these observations, Petridi 
et al (2019) found that dopaminergic knock-down completely ameliorated the TH>G2019S proboscis 
extension phenotype. This shows a difference between the global and dopaminergic knock-down of 
Rab10.      
The in vitro data generated by Alessi’s group suggests that Rab10 is phosphorylated by LRRK2 
(Steger et al., 2016). If this were to occur in vivo, the prediction was that flies with both knock-down 
of Rab10 and dopaminergic expression of G2019S should have had slower extension and increased 
tremor caused by disrupted vesicular transport in dopaminergic neurons, as found by Petridi et al. 
[2019]. Specific activities of hyperphorphorylated Rab10, such as preventing normal expression of 
GLUT4 transporters to the cell surface, improperly dealing with lysosomal stress, and preventing 
defective mitochondria from efficiently beginning mitophagy, may equally play a role in the 
development of this phenotype. Further experiments could be performed to establish these in the 
cell, for instance by measuring intracellular ROS levels by fluorometric determination. 
The synthetic interaction between TH>G2019S and Rab10¯ is different from this, and suggests that 
the Rab10 is having an effect elsewhere in the proboscis extension neural circuit. The main parts of 
the circuit are the Gr5a sensory neurons, the motor neurons and muscles. The genetic tools are 
available to achieve Rab10 knock-down in these components: e.g. Gr5a-GAL4, OK-6-GAL4 and mhc-
GAL4 respectively. Further it would be constructive to compare the effect of Rab10¯ with a global 
knock-down of Rab10 using a ubiquitous GAL4 (for example, Actin5c or daughterless). 
It is possible that the Rab10¯ has a second, off-target, mutation, which could explain the synthetic 
bradykinesia. To test this, it would be good to examine flies carrying both the Rab10¯ and expressing 
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UAS-Rab10:  
𝑅𝑎𝑏10𝐾𝑂 ; 
𝐺𝑟5𝑎𝐿𝑒𝑥𝐴 ∷ 𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅
𝑈𝐴𝑆 − 𝑅𝑎𝑏10
; 𝑇𝐻 − 𝐺𝑎𝑙4 ∷ 𝐺2019𝑆 
In such flies, Rab10 will be present in the dopaminergic neurons and would be expected to 
ameliorate any effects of the Rab10 null in these neurons.  
The data collected by Petridi et al (2019) confirmed in vivo that Rab10 could be phosphorylated by 
LRRK2, using the phospho-Rab10 antibody.  To test this further, rescue flies could be created in 
which Rab10 is replaced by a form which could not be phosphorylated or prenylated: 
𝑅𝑎𝑏10𝐾𝑂 ; 
𝐺𝑟5𝑎𝐿𝑒𝑥𝐴 ∷ 𝐿𝑒𝑥𝐴𝑜𝑝𝑅𝑒𝑎𝐶ℎ𝑅
𝑈𝐴𝑆 − 𝑅𝑎𝑏10 − 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑
; 𝑇𝐻 − 𝐺𝑎𝑙4 ∷ 𝐺2019𝑆 
 
5.3 Analysis of digitisation 
Two automated methods to determine the proboscis extension were tried (1) measuring the area of 
the fly head and (2) measuring the distance from the tip of the eye to the end of the proboscis. 
Method 1 suffered from errors in creating the binary (black/white) image from the head of the fly, 
which gave very variable area estimates from frame to frame. Method 2 was much more accurate, 
with consistent distances. This allowed the estimation of tremor which varies by genotype. However, 
if the fly rotates the head, so that the proboscis is not extended in a direct line, the actual extension 
may be underestimated. An example of this is shown in Figure 13 (magenta line). A second problem 
noted was that some flies, particularly those with the UAS-Rab10 construct, failed to fully extend 
their proboscis, which makes an automated system hard to achieve. Such partial extension may 
reflect a ‘hypokinesia’ phenotype, and it would be worth developing software further to measure 
this. 
Both methods suffered from the fact that proboscis extension began before the last flash had been 
given. Using a single flash, over before the start of the response, allowed Petridi et al [2019] to use 
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similar code to determine a more accurate trajectory, although it also meant that more flies must be 
tested to achieve the same power in statistical tests, as fewer of the flies exposed to a single flash    
produced a PER. 
Future Perspectives 
There is great scope for further research of Rab10’s role in Parkinson’s Disease. In light of Rab10 
being established as a likely next step in the pathway including VPS35, Rab29 and LRRK2, a new 
angle searching for PD therapies is to establish a mechanism whereby Rab10 over- or under-
expression may disrupt rate of glucose uptake, lysosomal stress relief, and mitophagy. The 
interaction between LRRK2 and Rab10 may also be important in pathogen neutralisation (Herbst and 
Gutierrez, 2019). It remains to be seen how LRRK2 signals in Crohn’s disease and in melanoma.  
A role for Rab10 in Alzheimer’s disease has been identified. A rare SNP in the 3’-untranslated region 
of Rab10 was found to confer significant resilience to individuals even with the major risk factor 
APOE ε4 allele, and knockout of Rab10 in vitro reduced the amount of a toxic variant of amyloid β 
(Aβ) protein found in cells (Tavana et al., 2019). Rab11 has been found to possibly function through 
amyloid clearance (Udayar et al., 2013). T-73-Rab10 has also been found to co-localise with Aβ 
plaques, and may contribute to Aβ build-up through reduced function of Rab10 allowing 
accumulation of Aβ in a similar mechanism to that of Rab11 (Yan et al., 2018). It is too early to tell if 
this is also linked to LRRK2 or if phosphorylation of Rab10 in Alzheimer’s is due to other kinases.  
However, the main impact of this work is on PD. Effects of LRRK2 and Rab10 on bradykinesia and 
tremor were determined in an unbiased, automated way in the fly model of PD. These effects 
occurred exclusively in dopaminergic neurons. In humans too, people with PD develop these 
phenotypes due to loss of dopaminergic neurons. As the condition advances, and progresses to 
akinesia or hypokinesia, they may be often incapacitated by severe tremor to the extent that 
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surgical intervention is considered preferable. It is logical therefore to maintain focus on activities of 
these proteins within dopaminergic neurons. 
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